United Kingdom

Baseimmune secures €10.4M Series A to develop AI-Predicted Mutation-Proof Vaccines
Baseimmune a London based biotech leveraging deep learning AI to predict pathogen mutations for vaccine development has raised $11 3M approximately €10 40M in a Series A funding round The investment was led by new investors MSD Global Health Innovation Fund and IQ Capital with participation from existing backers such as Hoxton Ventures Creator Fund Beast Ventures and Maki vc

The best Articles in our Network

Previous
Next